Last reviewed · How we verify
NCT02874859: MODEVA
Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema
trial in Diabetic Macular Edema in 49 participants. Completed in 19 August 2020.
19 August 2020
Quick facts
| Lead sponsor | Lille Catholic University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 49 |
| Start date | 9 November 2016 |
| Primary completion | 19 August 2020 |
| Estimated completion | 19 August 2020 |
| Sites | 8 locations across France |
Conditions studied
- Diabetic Macular Edema — all drugs for Diabetic Macular Edema →
Sponsor
Lille Catholic University
Who can join
Adults 18 to 90, any sex, with Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This a non-interventional retrospective study on the efficiency and the tolerance of intravitreal injections of Aflibercept on vitrectomized eyes in the diabetic macular oedema
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema.
Tran THC, Erginay A, Verdun S, Fourmaux E, et al · · 2021 · cited 7× · PMID 34007150 · DOI 10.2147/opth.s304030 -
Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema.
Tran THC, Verdun S, Le Rouic JF, Uzzan J, et al · · 2022 · cited 6× · PMID 35310546 · DOI 10.2147/opth.s352152
Verify or expand the search:
- PubMed search for NCT02874859
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Macular Edema
Currently open trials in the same condition.
- NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
- NCT06984822 — Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant · NA · recruiting
- NCT07038967 — Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification · recruiting
- NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
- NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting
Other Lille Catholic University trials
Trials by the same sponsor.
- NCT06634225 — Use of Inertial Units in Patient With Multiple Sclerosis (IMUSEP) · completed
- NCT06116929 — Hodgkin's Disease and Chemotherapy Before 40 Years · NA · not yet recruiting
- NCT05208099 — Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy · not yet recruiting
- NCT06318923 — Social and Moral Cognition in Multiple Sclerosis · NA · unknown
- NCT06083415 — Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02874859 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lille Catholic University
- Last refreshed: 5 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02874859.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing